PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 486.59% from the company’s previous close.

PDSB has been the topic of a number of other research reports. B. Riley decreased their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, June 12th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.25.

PDS Biotechnology Price Performance

Shares of PDS Biotechnology stock traded down $0.07 on Wednesday, hitting $3.58. The company’s stock had a trading volume of 351,640 shares, compared to its average volume of 638,744. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average price of $3.24 and a 200-day moving average price of $3.35. PDS Biotechnology has a 52-week low of $2.53 and a 52-week high of $6.85. The company has a market capitalization of $131.31 million, a P/E ratio of -2.63 and a beta of 1.88.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same period last year, the firm posted ($0.37) EPS. On average, equities research analysts expect that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently modified their holdings of the company. Inspirion Wealth Advisors LLC grew its stake in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after buying an additional 4,917 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in PDS Biotechnology during the 1st quarter worth $28,000. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology in the 2nd quarter valued at $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology in the second quarter valued at about $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology during the second quarter worth about $115,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.